Literature highlights the following points regarding future therapeutic targets beyond T2 pathways: tezepelumab, an anti-TSLP monoclonal antibody, is already approved for severe asthma in patients above 12 years, and, importantly, it is the first asthma biologic without restriction to specific biomarkers or inflammatory mechanisms of severe asthma. This evidence concerns the gene TSLP and asthma.